HOME >> BIOLOGY >> NEWS
Hepatitis C virus linked to non-Hodgkin's lymphoma

SEATTLE--Patients infected with the hepatitis C virus (HCV) are six times as likely to develop non-Hodgkin's lymphoma (NHL) than individuals that are virus free, according to research presented today at the Third Annual Frontiers in Cancer Prevention Research meeting.

HCV infected patients have a seventeen fold higher risk for developing diffuse large B-Cell lymphoma, researchers from British Columbia documented. Diffuse large B-cell lymphoma is the most common variety of NHL, comprising approximately 30 percent of all NHL patients.

Compared to Europe and Japan, incidence of hepatitis C viral infection is fairly low in North America, and previous studies from Canada and the United States have not shown an association between the virus and development of NHL, said Ms Agnes Lai, lead author for the research. The British Columbia study examined HCV status in 550 NHL cases and 205 population controls. The study had the strength of numbers of patients to ascertain an association between HCV and NHL, confirming the viral-cancer link suspected in studies from other areas of the world where the virus is more prevalent.

"People who have been exposed to the virus comprise a high risk group for developing non-Hodgkin's lymphoma, particularly diffuse b-cell lymphoma," said John Spinelli, a cancer researcher from the British Columbia Cancer Agency, Vancouver, BC, and principal investigator of the research study.

The spread of hepatitis C in the United States has dropped significantly since the 1980s. Currently, the number of new cases per year is around 25,000. Approximately 3.8 million Americans have been infected with the virus. The most common means of infection in the past was blood transfusion, and in recent years is among drug users who share needles.

Approximately 53,000 patients were diagnosed with NHL in the United States in 2003. There were 23,000 deaths from the disease that year.

Spinelli and Lai conducted their research wi
'"/>

Contact: Warren Froelich
communications@aacr.org
206-219-4772
American Association for Cancer Research
17-Oct-2004


Page: 1 2

Related biology news :

1. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process
2. Hepatitis B drug can compromise HIV treatment
3. Hepatitis E takes a piggyback
4. New hope for Hepatitis C research
5. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
6. New insights into protein synthesis and Hepatitis C infections
7. Hepatitis B accounts for 40 percent of missing Asian women
8. Hepatitis C complicated by morphine withdrawal
9. Identification of a protein important for Hepatitis B replication
10. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
11. Features of replication suggest viruses have common themes, vulnerabilities

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/30/2020)... ... May 29, 2020 , ... ... for enterprises globally, has collaborated with EchoNous Inc. to develop the cloud-based connected ... measure systolic heart function, which has been clinically tested versus expert measurements, yielding ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing ... engagers and TCR-based therapeutics, has implemented Genedata Biologics ® within their ...
(Date:5/21/2020)... ... 2020 , ... Law Enforcement has always been a highly stressful career – ... of these men and women put them constantly in harm’s way both from the ... have always had to face very high daily stress. Now, COVID-19 introduces another even ...
Breaking Biology News(10 mins):
(Date:5/26/2020)... ... 2020 , ... Brilliant , the leading smart home control and lighting ... announce a new integration to bring more convenience, simplicity, and security to the smart ... Connect® can now be controlled from Brilliant’s in-wall touchscreen control panels and mobile app. ...
(Date:5/21/2020)... ... May 20, 2020 , ... ... Simon Prakash, who will serve as the company’s executive vice president of product ... when Exo is disrupting the medical imaging space, bringing more than 24 years ...
(Date:5/15/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has ... Miller and Sentien’s management team. , Mr. Ganz has more than 30 ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early stages of drug discovery ... no information on the drug’s mechanism of action (MOA). Gene expression profiling technologies ... the activity of molecular pathways. This information can complement phenotypic readouts and can ...
Breaking Biology Technology:
Cached News: